MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
MDXG 10.40 Mimedx Group Inc $MDXG Hit a 52 week high of 10.50 Closing the day 09:44 at 10.40 -0.04 -0.38% With a day low of 10.35 and a total volume of 8,685.

MDXG Recent Posts: http://investorshangout.com/MiMedx-Group-Inc-MDXG-64149/

MDXG Mimedx Group Inc Recent Headline News

MiMedx elects Christopher M. Cashman as EVP
M2 - Mon Nov 10, 8:11AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) announced on Friday that it has appointed Christopher M. Cashman as its executive vice president & chief commercialisation officer.
MDXG: 10.39 (-0.05)

MiMedx® Adds New Executive
PR Newswire - Fri Nov 07, 8:39AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
MDXG: 10.39 (-0.05)

Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.01 (-0.06), OPK: 8.27 (-0.07), VNDA: 11.93 (-0.24), MDXG: 10.39 (-0.05), PDLI: 7.75 (-0.14)

MiMedx To Present At Two Healthcare Conferences
PR Newswire - Wed Nov 05, 1:59PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at two healthcare conferences in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014 at 11:30 am EST at the Palace Hotel. Management will also present at 8:00 am EST on Thursday, November 20, 2014, at the Canaccord|Genuity Forum, which is being held at the Westin Grand Central Hotel. Webcasts of each presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.39 (-0.05)

MiMedx raises full year 2014 guidance after Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:42AM CDT

MDXG: 10.39 (-0.05)

MiMedx Group's (MDXG) CEO Parker Petit on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 4:54PM CDT

MDXG: 10.39 (-0.05)

MiMedx Group beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 8:11AM CDT

MDXG: 10.39 (-0.05)

MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.39 (-0.05)

Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.39 (-0.05)

MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.39 (-0.05)

Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.39 (-0.05)

Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.39 (-0.05)

MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.39 (-0.05)

MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.39 (-0.05)

MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 8.35 (-0.04), MYGN: 32.85 (-0.50), HALO: 8.48 (-0.26), MDXG: 10.39 (-0.05)

MiMedx Group's (MDXG) CEO Pete Petit Hosts Analyst Day (Transcript)
SA Transcripts - at Seeking Alpha - Tue Oct 14, 7:13PM CDT

MDXG: 10.39 (-0.05)

MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.39 (-0.05)

MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.39 (-0.05)

MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.39 (-0.05)

MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM" allograft products to Zimmer to be marketed non- exclusively on a private label basis.
MDXG: 10.39 (-0.05)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 152

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 103

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 70

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 30

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 85

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading

Top 5 Most Recently Viewed Articles

Penske's Q3 2026: Revenue Up, Private Deal Awaits

Updated Category News Views 189

Jumping straight into it, Penske Automotive Group (NYSE: PAG) just rolled out their quarterly numbers. The highlights? A 5% revenue bump, landing at $8.4 billion. That's nice, sure, but let's not get too cozy, there's a bigger elephant in this garage—it's the bold move to take the company private! Our old friend volatility still sends shivers down the spine of long-time...

Continue Reading
Shanghai Hosts 20th Global Entrepreneurship Week

Updated Category News Views 226

Shanghai: A Hacker's Paradise of Innovation? The heart of financial ambition beats loud and clear in Shanghai this time of year. November 10 to 14, 2026, promises to be a spectacle of entrepreneurial valor as the city hosts the 20th Global Entrepreneurship Week China. This isn't just some run-of-the-mill networking shindig; we're talking about over 50 dazzling events,...

Continue Reading
Strategic Merger of BerGenBio and Oncoinvent Bolsters Growth

Updated Category News Views 247

BerGenBio and Oncoinvent Proposed Merger Overview In a significant development within the biotechnology sector, BerGenBio ASA and Oncoinvent ASA have announced their plans for a merger. The merger aims to combine both companies into a single entity with BerGenBio as the acquiring company, fostering a collaborative approach to advancing innovative cancer therapies. Details...

Continue Reading
Cloud-Native Application Protection Platform Market Sees Surge

Updated Category News Views 89

Cloud-Native Application Protection Platform Market Surge The Cloud-Native Application Protection Platform (CNAPP) market is witnessing remarkable growth, recently reported to be nearly $700 million in the second quarter of 2024. This represents a staggering 42 percent increase year-over-year. The recent findings emphasize how companies are prioritizing cloud security as...

Continue Reading
Arkay Zero Proof's Bold Move with $6 Million Times Square Launch

Updated Category News Views 319

Arkay Zero Proof Takes Times Square by Storm with Major Campaign Arkay Zero Proof, known for its innovative non-alcoholic spirits, is making headlines with a bold advertising initiative in the bustling Times Square. With a remarkable investment of $6 million, this campaign aims to enhance Arkay's brand visibility while reinforcing its position in the thriving market of...

Continue Reading